NBE-Therapeutics obtained CHF 600K SystemsX grant28.11.2014 11:30
NBE-Therapeutics is industry partner in a Swiss SystemsX funded transfer-project together with Prof. Zippelius of University Hospital Basel.
NBE-Therapeutics today announced that it has been awarded a grant for a transfer project of CHF 600K volume supported by the Swiss federal SystemsX initiative. The grant is intended to support a collaboration of NBE-Therapeutics together with the group of Prof. Alfred Zippelius from the Department Biomedicine and the Clinical Oncology of the University Hospital Basel, as the lead academic investigator, and the group of Prof. Sai Reddy at the Basel-based Department for Biosystems Science and Engineering (D-BSSE) of ETH-Zurich. The collaboration is focused on studying synergies between antibody drug conjugate-based therapy developed by NBE-Therapeutics with other immune-therapeutic interventions, in order to find the most effective therapies for cancer patients.
NBE-Therapeutics AG is a biotechnology company located in Basel, Switzerland. The company was founded in 2012 by serial entrepreneur Ulf Grawunder. NBE-Therapeutics is focusing on the development of antibody drug conjugates (ADCs) for the therapy of cancer. ADCs are a new type of targeted therapy, in which highly potent cellular toxins (toxic payloads) are conjugated to cancer-specific antibodies allowing the targeted destruction of cancer cells without affecting healthy cells or tissue. The company has developed Transpo-mAb, a fully human therapeutic antibody discovery platform, as well as the SMAC-Technology, an enzymatic payload conjugation platform, for the generation of homogeneous next-generation ADCs. The SMAC-Technology was validated in proof-of-concept studies.